Direct-to-consumer digital care firm Hims & Hers is the newest digital well being firm to announce it should add GLP-1 drugs to its choices to help customers with weight loss administration.
The San Francisco-based firm, which launched its weight loss program in December, stated customers will now have entry to generic and 503B compounded injectable drugs and oral medicine kits for weight administration beginning at $199 a month.
In a press release, the corporate stated its drugs will probably be extra available than model names like Ozempic or Wegovy thanks to a partnership with a U.S. producer of generic variations of GLP-1s.
“We’ve leveraged our dimension and scale to safe entry to one of many highest-quality provides of compounded GLP-1 injections obtainable at present. We’re passing that entry and worth alongside to our prospects, who deserve the best customary of scientific security and efficacy to meet their targets, and we’re doing it in a secure, reasonably priced manner that others can’t ship,” Andrew Dudum, CEO and cofounder of Hims & Hers, stated in a press release.
THE LARGER TREND
Researchers proceed to consider the security of GLP-1 drugs for long-term use.
One research printed within the International Journal of Clinical Pharmacy revealed there may be rising knowledge on the potential of pancreatic carcinoma related to GLP-1 receptor agonists.
However, one other research printed in JAMA Network Open confirmed that researchers discovered no assist for elevated pancreatic most cancers incidence after seven years following the beginning of GLP-1 therapy.
Other firms which have added GLP-1-focused choices to their platform embrace digital chronic-condition administration firm Lark Health.
Digital weight loss firm Noom introduced its business enterprise, Noom for Work, and nationwide pharmacy profit supervisor Liviniti have been partnering to provide plan sponsors and their staff a digital GLP-1 Companion for power weight circumstances.